Our data indicated that BRCA2 carriers with DCIS were tend to be ER‐positive (p = 0.042) no matter with the age of patients, and subgroup analysis showed BRCA2 tumors with DICS was higher in expression of ER+/PR+ (p = 0.049). The gene discussed is BRCA2; the disease is ductal breast carcinoma in situ.